寻常型天疱疮患者特殊情况下治疗的注意事项

doi:10.35541/cjd.20210161

中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (11): 1078-1080.doi: 10.35541/cjd.20210161

寻常型天疱疮患者特殊情况下治疗的注意事项

王倩江水邹雅茹陈宏泉陈官芝郁博邹慧储鑫

青岛大学附属医院皮肤性病科，青岛 266003

收稿日期:2021-02-26 修回日期:2022-03-15 发布日期:2023-11-03
通讯作者: 郁博 E-mail:yuangela76@126.com
基金资助:
山东省医药卫生科技发展计划项目（2017WS636）

Considerations during the treatment of pemphigus vulgaris under special circumstances

Wang Qian, Jiang Shui, Zou Yaru, Chen Hongquan, Chen Guanzhi, Yu Bo, Zou Hui, Chu Xin

Department of Dermatology and Venereology, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong, China

Received:2021-02-26 Revised:2022-03-15 Published:2023-11-03
Contact: Yu Bo E-mail:yuangela76@126.com
Supported by:
Shandong Province Medical and Health Science and Technology Development Plan Project（2017WS636）

摘要/Abstract

摘要： 【摘要】寻常型天疱疮是天疱疮中最常见和最严重的一种类型，及时治疗可以改变其预后。本文综合分析寻常型天疱疮患者治疗过程中的注意事项，包括妊娠期和哺乳期以及新型冠状病毒肺炎防控期间治疗的特殊性、综合护理等，为患者提供完善的指导和治疗。

关键词: 寻常型天疱疮, 诱发因素, 药物不良反应, 妊娠期, 哺乳期, 新冠肺炎, 护理, 预后

Abstract: 【Abstract】 Pemphigus vulgaris is the most common and serious type of pemphigus, and timely treatment can change its prognosis. This review comprehensively analyzes considerations in the treatment of pemphigus vulgaris during pregnancy and lactation as well as during the prevention and control of COVID-19 pandemic, including treatment particularities and comprehensive nursing care, in order to provide better guidance and treatment for patients.

Key words: pemphigus vulgaris, inducing factors, adverse drug reactions, pregnancy, lactation, COVID-19, nursing, prognosis

王倩江水邹雅茹陈宏泉陈官芝郁博邹慧储鑫. 寻常型天疱疮患者特殊情况下治疗的注意事项[J]. 中华皮肤科杂志, 2023,56(11):1078-1080. doi:10.35541/cjd.20210161

Wang Qian, Jiang Shui, Zou Yaru, Chen Hongquan, Chen Guanzhi, Yu Bo, Zou Hui, Chu Xin. Considerations during the treatment of pemphigus vulgaris under special circumstances[J]. Chinese Journal of Dermatology, 2023, 56(11): 1078-1080.doi:10.35541/cjd.20210161

参考文献 20

［1］	Pundir S, Gridneva Z, Pillai A, et al. Human milk glucocorticoid levels are associated with infant adiposity and head circumference over the first year of life［J］. Front Nutr, 2020,7:166. doi: 10.3389/fnut.2020.00166.
［2］	Rademaker M, Agnew K, Andrews M, et al. Psoriasis in those planning a family, pregnant or breast⁃feeding. The Australasian Psoriasis Collaboration［J］. Australas J Dermatol, 2018,59（2）:86⁃100. doi: 10.1111/ajd.12641.
［3］	Kushner CJ, Concha J, Werth VP. Treatment of autoimmune bullous disorders in pregnancy［J］. Am J Clin Dermatol, 2018,19（3）:391⁃403. doi: 10.1007/s40257⁃018⁃0342⁃0.
［4］	Lee KM, Kim YS, Seo GS, et al. Use of thiopurines in inflammatory bowel disease: a consensus statement by the Korean association for the study of intestinal diseases （KASID）［J］. Intest Res, 2015,13（3）:193⁃207. doi: 10.5217/ir.2015.13. 3.193.
［5］	Patsatsi A, Marinovic B, Murrell D. Autoimmune bullous diseases during pregnancy: solving common and uncommon issues［J］. Int J Womens Dermatol, 2019,5（3）:166⁃170. doi: 10.1016/j.ijwd. 2019.01.003.
［6］	Tavakolpour S, Mirsafaei HS, Delshad S. Management of pemphigus disease in pregnancy［J］. Am J Reprod Immunol, 2017,77（1）. doi: 10.1111/aji.12601.
［7］	Hoffmann F, Kraft A, Heigl F, et al. Tryptophan immunoadsorption for multiple sclerosis and neuromyelitis optica: therapy option for acute relapses during pregnancy and breastfeeding［J］. Nervenarzt, 2015,86（2）:179⁃186. doi: 10.1007/ s00115⁃014⁃4239⁃8.
［8］	Wan J, Imadojemu S, Werth VP. Management of rheumatic and autoimmune blistering disease in pregnancy and postpartum［J］. Clin Dermatol, 2016,34（3）:344⁃352. doi: 10.1016/j.clindermatol. 2016.02.006.
［9］	Chi CC, Wang SH, Kirtschig G. Safety of topical corticosteroids in pregnancy［J］. JAMA Dermatol, 2016,152（8）:934⁃935. doi: 10.1001/jamadermatol.2016.1009.
［10］	Chi CC, Kirtschig G, Aberer W, et al. Updated evidence⁃based （S2e） European Dermatology Forum guideline on topical corticosteroids in pregnancy［J］. J Eur Acad Dermatol Venereol, 2017,31（5）:761⁃773. doi: 10.1111/jdv.14101.
［11］	Zhao CY, Chiang YZ, Murrell DF. Neonatal autoimmune blistering disease: a systematic review［J］. Pediatr Dermatol, 2016,33（4）:367⁃374. doi: 10.1111/pde.12859.
［12］	Pawar M, Singh M. Systemic steroids and risk of fecal⁃oral shedding and increased transmission of SARS⁃CoV⁃2 in pemphigus cases［J］. Clin Dermatol, 2020,38（6）:750⁃756. doi: 10.1016/j.clindermatol.2020.06.006.
［13］	Campanati A, Brisigotti V, Diotallevi F, et al. Active implications for dermatologists in ′SARS⁃CoV⁃2 ERA′: personal experience and review of literature［J］. J Eur Acad Dermatol Venereol, 2020，34（8）:1626⁃1632. doi: 10.1111/jdv.16646.
［14］	Elmas ÖF, Demirbaş A, Türsen Ü, et al. Pemphigus and COVID⁃19: Critical overview of management with a focus on treatment choice［J］. Dermatol Ther, 2020,33（6）:e14265. doi: 10.1111/dth.14265.
［15］	Kasperkiewicz M, Yale M, Strong R, et al. COVID⁃19 pandemic and autoimmune bullous diseases: a cross⁃sectional study of the International Pemphigus and Pemphigoid Foundation［J］. J Eur Acad Dermatol Venereol, 2021,35（7）:e418⁃e421. doi: 10.1111/jdv.17228.
［16］	Atarzadeh F, Daneshfard B, Dastgheib L, et al. Early description of diet⁃induced blistering skin diseases in medieval Persia: Avicenna′s point of view［J］. Skinmed, 2016,14（5）:367⁃370.
［17］	Kneiber D, Kowalski EH, Kridin K, et al. Gastrointestinal symptoms, gastrointestinal bleeding and the role of diet in patients with autoimmune blistering disease: a survey of the International Pemphigus and Pemphigoid Foundation［J］. J Eur Acad Dermatol Venereol, 2019,33（10）:1935⁃1940. doi: 10.1111/ jdv.15731.
［18］	Pedroni MN, Hirotsu C, Porro AM, et al. The role of sleep in pemphigus: a review of mechanisms and perspectives［J］. Arch Dermatol Res, 2017,309（8）:659⁃664. doi: 10.1007/s00403⁃017⁃1765⁃9.
［19］	Li F, Wu Y, Bian W, et al. Features and associated factors of bacterial skin infections in hospitalized patients with pemphigus: a single⁃center retrospective study［J］. Ann Clin Microbiol Antimicrob, 2020,19（1）:46. doi: 10.1186/s12941⁃020⁃00388⁃6.
［20］	Takahashi H, Iriki H, Mukai M, et al. Autoimmunity and immunological tolerance in autoimmune bullous diseases［J］. Int Immunol, 2019,31（7）:431⁃437. doi: 10.1093/intimm/dxz030.

[1]	焦晓燕尹光文李冬芹阴亚坤蔡丙杰方慧. 伴脑卒中的大疱性类天疱疮74例临床分析[J]. 中华皮肤科杂志, 2023, 56(4): 330-334.
[2]	曹淼崇杉王明悦. 不同浸浴方案对天疱疮患者皮损愈合的影响分析[J]. 中华皮肤科杂志, 2023, 56(1): 49-53.
[3]	曹淼崇杉胡新媛朱学骏王明悦. 副肿瘤性天疱疮患者原发肿瘤切除后皮肤黏膜感染及管理分析[J]. 中华皮肤科杂志, 2022, 55(8): 669-675.
[4]	王倩漆波张丽霞刘伟兰蕴平. SCORTEN和ABCD-10评估Stevens-Johnson综合征/中毒性表皮坏死松解症预后的比较[J]. 中华皮肤科杂志, 2022, 55(7): 566-570.
[5]	张晓陈凤鸣柳琳罗莉郭金高天文石琼. Ⅰ期皮肤黑素瘤163例临床病理特征及预后分析[J]. 中华皮肤科杂志, 2022, 55(5): 389-394.
[6]	王海彦鄢洁曹馨元石长青刘菁陆晓鸥张嘉莉陈宏泉. 基于SEER数据库的肢端雀斑样痣黑素瘤预后分析[J]. 中华皮肤科杂志, 2022, 55(5): 411-416.
[7]	李浩, 王俐韩宪伟孙彤苏芳孙晓冬韩莹杨国玲刘晓明王凯波 . 糖尿病患者服用二肽基肽酶Ⅳ抑制剂后发生大疱性类天疱疮32例临床特征分析[J]. 中华皮肤科杂志, 2022, 55(3): 213-218.
[8]	吕玲吕小岩. 皮肌炎伴发恶性肿瘤的研究进展[J]. 中华皮肤科杂志, 2022, 55(3): 276-279.
[9]	林羽洁, 刘凤洁, 高玉梅, 刘向君, 许卜方, 李映依, 赖盼, 陈卓婧, 孙婧茹, 涂平, 汪旸. 溶血磷脂酸受体6在蕈样肉芽肿向大细胞转变中的意义及其对皮肤T细胞淋巴瘤细胞增殖和凋亡的影响[J]. 中华皮肤科杂志, 2022, 55(2): 102-109.
[10]	焦晓燕尹光文阴亚坤李冬芹. 妊娠期、围生期带状疱疹25例临床分析[J]. 中华皮肤科杂志, 2022, 55(10): 881-884.
[11]	高美艳赵建红赵涛李冰田佩王冠马翠玲高天文郭伟楠. 外伤相关黑素瘤87例临床病理特点与预后分析[J]. 中华皮肤科杂志, 2021, 54(4): 289-293.
[12]	谢波尉晓冬许爱娥林福全周妙妮. 系统糖皮质激素治疗进展期白癜风的疗效及相关因素研究[J]. 中华皮肤科杂志, 2021, 54(2): 139-144.
[13]	张晓朱冠男张少龙王刚. 182例天疱疮患者合并感染状况的回顾分析[J]. 中华皮肤科杂志, 2020, 53(1): 8-12.
[14]	缪秋菊宋昊王逸飞徐秀莲孙建方. 皮下结节型结节病八例临床病理分析[J]. 中华皮肤科杂志, 2019, 52(11): 808-811.
[15]	王志伟李伟人郑德义杜娇王毅柴磊刘莉韩庆玲. 皮肤Merkel细胞癌171例临床及病理回顾分析[J]. 中华皮肤科杂志, 2018, 51(9): 695-698.

寻常型天疱疮患者特殊情况下治疗的注意事项

Considerations during the treatment of pemphigus vulgaris under special circumstances

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 20

相关文章 15

Metrics

本文评价

推荐阅读 10